Nicole Concin, MD, professor, experimental gynecology, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, discusses the patient population that enrolled in the phase ​1b/2 LIO-1 trial in advanced gynecologic malignancies.

 will enroll approximately 161 patients with advanced​, recurrent, or metastatic gynecological malignancies, Concin says.

Four cohorts will ​be include​d in the study: endometrial cancer, cervical cancer, ovarian cancer excluding clear-cell histology, and clear-cell ovarian/endometrial cancer.

Clear-cell ​gynecologic carcinoma is a rare disease, so the inclusion of this subtype is a unique feature of the study, ​explains Concin.

​The LIO-1 trial will evaluate the safety and efficacy of the investigational TKI lucitanib and nivolumab (Opdivo) in this patient population.

Videos

Nicole Concin, MD, discusses the patient population that enrolled in the phase ​1b/2 LIO-1 trial in advanced gynecologic malignancies.

Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic Malignancies 

Nicole Concin, MD, professor, experimental gynecology, Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria, discusses the rationale for the ​phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

The phase 2 portion of the LIO-1 trial will evaluate the safety and efficacy of lucitanib, an investigational ​and potent TKI that inhibits VEGFR 1-3, PDGFRα/β, and FGFR 1-3, in combination with nivolumab (Opdivo) in patients with advanced ​gynecologic solid tumors, says Concin.

Notably, the rationale to combine angiogenesis inhibitors with immunotherapy is based on preclinical data that demonstrated increased efficacy with this approach, Concin concludes.

Nicole Concin, MD, discusses the rationale for the ​phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

Nicole Concin, MD

Articles

Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic Malignancies

Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies